穿刺未检出的筛状和导管内前列腺癌与不良结局相关
研究纳入2015年1月至2022年12月行根治性前列腺切除术的836例患者,评估穿刺对导管内癌(IDC)和筛状结构(Crib)假阴性对肿瘤学结局的影响。假阴性穿刺者病理分期≥pT3率为56.8%,真阴性者为28.1%(p<0.001);多因素Cox分析显示假阴性穿刺与生化复发风险升高独立相关(HR 2.14,95%CI 1.41-3.25;p<0.001)。
要点
- 穿刺对IDC/Crib假阴性者病理分期≥pT3率为56.8%,真阴性者为28.1%(p<0.001)。
- 假阴性穿刺与生化复发风险升高独立相关(HR 2.14,95%CI 1.41-3.25;p<0.001)。
- 术前log PSA(HR 2.07)和阳性针数≥33%(HR 1.68)也与生化复发风险升高相关。
核心结论
- 与真阴性穿刺相比,穿刺对IDC/Crib假阴性独立与更高的生化复发风险和更晚的病理分期相关。
研究设计与样本
- 研究纳入2015年1月至2022年12月期间行根治性前列腺切除术的患者,共836例。
- 采用多因素Cox比例风险模型分析生化失败预测因素。
主要发现
- 836例患者中,233例(27.9%)穿刺有Crib,125例(15.0%)有IDC,71例(8.5%)同时有IDC和Crib。
- 关于穿刺IDC/Crib状态,217例(26%)为假阴性,332例(39.7%)为真阴性,256例(30.6%)为真阳性,24例(3.7%)为假阳性。
- 假阴性穿刺者病理分期≥pT3率为56.8%,真阴性者为28.1%(p<0.001)。
- 多因素Cox分析显示,术前log PSA(HR 2.07,95%CI 1.53-2.82;p<0.001)、穿刺阳性针数≥33%(HR 1.68,95%CI 1.07-2.63;p=0.024)和IDC/Crib假阴性穿刺(HR 2.14,95%CI 1.41-3.25;p<0.001)均与生化复发风险升高显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraductal carcinoma (IDC) and cribriform pattern (Crib) of prostate cancer are increasingly recognized as independent prognosticators of poor outcome, both in prostate biopsies and radical prostatectomy (RP) specimens. OBJECTIVE: The aim of our project is to assess the impact of false negative biopsies for these two characteristics on oncological outcomes. MATERIAL AND METHODS: Patients who underwent RP between January 2015 and December 2022 were included in the study. Predictors of Biochemical Failure were examined using a multivariate Cox proportional hazards model. RESULTS AND LIMITATION: Among the 836 patients who underwent RP, 233 (27.9%) had Crib, and 125 (15.0%) had IDC on prostate biopsy, with 71 (8.5%) patients having both IDC and Crib. Concerning IDC/Crib status at biopsy, 217 (26%) patients had a false-negative biopsy, 332 (39.7%) had a true-negative biopsy, 256 (30.6%) showed a true-positive biopsy, and 24 (3.7%) exhibited a false-positive biopsy, with respect to either pattern. When comparing false-negative, false-positive, true-negative and true-positive biopsies for IDC/Crib, we found that patients with a false-negative biopsy for IDC/Crib versus those with a true-negative biopsy for IDC/Crib disclosed a rate of advanced pathological stage (≥pT3) which was twice that of patients with a true-negative biopsy for IDC/Crib: 56.8% versus 28.1%, respectively (p < 0.001). On multivariate Cox analysis, log PSA before RP (hazard ratio [HR] 2.07, 95% CI 1.53-2.82; p < 0.001), a higher percentage of positive cores at biopsy ( ≥ 33%) (HR 1.68, 95% CI 1.07-2.63; p = 0.024), and false negative biopsy for IDC/Crib (HR 2.14, 95% CI 1.41-3.25; p < 0.001), were each significantly associated with an increased risk of BCR. CONCLUSIONS: A false-negative biopsy for IDC/Crib is independently associated with higher risk of BCR and advanced pathological stage compared to a true negative biopsy.
引用
- Bernardino RM, Yin LB, Lajkosz K, et al. Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes. Prostate Cancer Prostatic Dis. 2024. PMID: 39433886. doi:10.1038/s41391-024-00910-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。